A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)

Trial Profile

A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Alprostadil (Primary)
  • Indications Raynaud's disease
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors Apricus Biosciences; NexMed (USA)
  • Most Recent Events

    • 12 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 17 Sep 2015 Status changed from active, no longer recruiting to completed according to an Apricus Biosciences media release.
    • 17 Sep 2015 Top-line results published in an Apricus Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top